$17.23
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. The company is headquartered in Vaughan, Ontario and currently employs 13,000 full-time employees. The company went IPO on 2022-05-06. The company operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Country

CA

CEO

Mr. Brenton Saunders

IPO date

2022

Employees

13,000

ISIN

CA0717051076

Key stats

Open

$17.36

Volume

239.92K

Market cap

$6.16B

Prev. close

$17.23

Impl / hst vl

-

Open interest

$0.00

$17.16

Day’s Range

$17.53

$14.65

52W Range

$18.92

Valuation

50
Valuation score
Fairly Valued
P/E
-
P/S
1.14
P/B
0.95
Current ratio
1.55
Debt / Equity
0.80
ROE
-2.67%
Gross margin
62.20%
Income growth
-80.28%
FCF growth
-220.59

Analysts estimates

Consensus rating
Buy

The average rating from top 7 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$18.92
The top 13 analysts forecasts that 12-month price may increase by 9.79%, with a low of $16.16 and a high of $24.15
$16.16
Low
$18.92
Avg
$24.15
High
Current price

Earnings

Q2 ‘26 revenue
$1.39B
Q2 ‘26 net income
-$14.00M
Revenue
Net income
Previous EPS
$0.08
Estimate EPS
$0.16
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply